Literature DB >> 20197101

Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation.

Saro H Armenian1, Can-Lan Sun, George Mills, Jennifer Berano Teh, Liton Francisco, Jean-Bernard Durand, F Lennie Wong, Stephen J Forman, Smita Bhatia.   

Abstract

Long-term survival after hematopoietic cell transplantation (HCT) is now an expected outcome. The growing population of survivors is at risk of developing treatment-related complications, including cardiovascular disease (CVD). A nested case-controlled design was used to identify clinical and treatment-related risk factors for development of late (1+ years after HCT) CVD. Cases were identified from a cohort of 1+-year survivors who underwent transplantation at City of Hope between 1977 and 2006. Controls (HCT survivors without CVD) were matched on age, year of HCT, type of HCT, and duration of follow-up. Sixty-three patients with late CVD were identified, 44 (69.8%) with a coronary artery event and 19 (30.2%) with a cerebrovascular event. Median age at HCT was 49.0 years. Median age at onset of late CVD was 54.0 years; 66.7% of the affected patients had undergone autologous HCT. Multivariate logistic regression analysis showed that the presence of multiple cardiovascular risk factors (2 or more of the following: obesity, dyslipidemia, hypertension, and diabetes) after HCT was associated with a 5.2-fold increased risk of late CVD (P < .01), and that pre-HCT chest radiation exposure was associated with a 9.5-fold greater risk of coronary artery disease (P = .03). Pre-HCT exposure to chest radiation and the presence of comorbidities were primarily responsible for the risk associated with late CVD after HCT. These data form the basis for developing predictive models for identifying high-risk individuals for targeted surveillance and aggressive management of comorbidities.

Entities:  

Mesh:

Year:  2010        PMID: 20197101      PMCID: PMC2888883          DOI: 10.1016/j.bbmt.2010.02.021

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  42 in total

Review 1.  Inflammation, atherosclerosis, and coronary artery disease.

Authors:  Göran K Hansson
Journal:  N Engl J Med       Date:  2005-04-21       Impact factor: 91.245

2.  Standards for statistical models used for public reporting of health outcomes: an American Heart Association Scientific Statement from the Quality of Care and Outcomes Research Interdisciplinary Writing Group: cosponsored by the Council on Epidemiology and Prevention and the Stroke Council. Endorsed by the American College of Cardiology Foundation.

Authors:  Harlan M Krumholz; Ralph G Brindis; John E Brush; David J Cohen; Andrew J Epstein; Karen Furie; George Howard; Eric D Peterson; Saif S Rathore; Sidney C Smith; John A Spertus; Yun Wang; Sharon-Lise T Normand
Journal:  Circulation       Date:  2005-12-19       Impact factor: 29.690

Review 3.  Hematopoietic stem-cell transplantation.

Authors:  Edward A Copelan
Journal:  N Engl J Med       Date:  2006-04-27       Impact factor: 91.245

4.  Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation.

Authors:  J Douglas Rizzo; John R Wingard; Andre Tichelli; Stephanie J Lee; Maria Teresa Van Lint; Linda J Burns; Stella M Davies; James L M Ferrara; Gérard Socié
Journal:  Biol Blood Marrow Transplant       Date:  2006-02       Impact factor: 5.742

Review 5.  Inflammation, atherosclerosis, and stroke.

Authors:  Mitchell S V Elkind
Journal:  Neurologist       Date:  2006-05       Impact factor: 1.398

6.  Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study.

Authors:  K Scott Baker; Kirsten K Ness; Julia Steinberger; Andrea Carter; Liton Francisco; Linda J Burns; Charles Sklar; Stephen Forman; Daniel Weisdorf; James G Gurney; Smita Bhatia
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

7.  Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls.

Authors:  Karen L Syrjala; Shelby L Langer; Janet R Abrams; Barry E Storer; Paul J Martin
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

8.  Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer.

Authors:  Alexandra W van den Belt-Dusebout; Janine Nuver; Ronald de Wit; Jourik A Gietema; Wim W ten Bokkel Huinink; Patrick T R Rodrigus; Erik C Schimmel; Berthe M P Aleman; Flora E van Leeuwen
Journal:  J Clin Oncol       Date:  2006-01-20       Impact factor: 44.544

Review 9.  Inflammation and atherosclerosis: novel insights into plaque formation and destabilization.

Authors:  Guido Stoll; Martin Bendszus
Journal:  Stroke       Date:  2006-06-01       Impact factor: 7.914

10.  Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline.

Authors:  Wendy Landier; Smita Bhatia; Debra A Eshelman; Katherine J Forte; Teresa Sweeney; Allison L Hester; Joan Darling; F Daniel Armstrong; Julie Blatt; Louis S Constine; Carolyn R Freeman; Debra L Friedman; Daniel M Green; Neyssa Marina; Anna T Meadows; Joseph P Neglia; Kevin C Oeffinger; Leslie L Robison; Kathleen S Ruccione; Charles A Sklar; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2004-12-02       Impact factor: 44.544

View more
  35 in total

1.  Changes in echocardiographic measures of systolic and diastolic function in children 1 year after hematopoietic SCT.

Authors:  K P Daly; S D Colan; E D Blume; R Margossian; K Gauvreau; C Duncan; L E Lehmann; M H Chen
Journal:  Bone Marrow Transplant       Date:  2011-01-31       Impact factor: 5.483

2.  Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation.

Authors:  Bradley W Blaser; Haesook T Kim; Edwin P Alyea; Vincent T Ho; Corey Cutler; Philippe Armand; John Koreth; Joseph H Antin; Jorge Plutzky; Robert J Soiffer
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-11       Impact factor: 5.742

3.  Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma.

Authors:  Amrita Krishnan; Joycelynne M Palmer; Ni-Chun Tsai; Jennifer R Simpson; Auayporn Nademanee; Andrew Raubitschek; Sandra H Thomas; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-27       Impact factor: 5.742

Review 4.  Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up.

Authors:  Smita Bhatia
Journal:  Expert Rev Hematol       Date:  2011-08       Impact factor: 2.929

5.  Late cardiovascular complications after hematopoietic cell transplantation.

Authors:  Eric J Chow; Kenneth Wong; Stephanie J Lee; Kara L Cushing-Haugen; Mary E D Flowers; Debra L Friedman; Wendy M Leisenring; Paul J Martin; Beth A Mueller; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-22       Impact factor: 5.742

6.  Cardiovascular Function in Long-Term Hematopoietic Cell Transplantation Survivors.

Authors:  Saro H Armenian; David Horak; Jessica M Scott; George Mills; Aida Siyahian; Jennifer Berano Teh; Pamela S Douglas; Stephen J Forman; Smita Bhatia; Lee W Jones
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-05       Impact factor: 5.742

7.  National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines.

Authors:  Michael A Pulsipher; Roderick Skinner; George B McDonald; Sangeeta Hingorani; Saro H Armenian; Kenneth R Cooke; Clarisa Gracia; Anna Petryk; Smita Bhatia; Nancy Bunin; Michael L Nieder; Christopher C Dvorak; Lillian Sung; Jean E Sanders; Joanne Kurtzberg; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2012-01-14       Impact factor: 5.742

8.  Prediction of cardiovascular disease among hematopoietic cell transplantation survivors.

Authors:  Saro H Armenian; Dongyun Yang; Jennifer Berano Teh; Liezl C Atencio; Alicia Gonzales; F Lennie Wong; Wendy M Leisenring; Stephen J Forman; Ryotaro Nakamura; Eric J Chow
Journal:  Blood Adv       Date:  2018-07-24

9.  Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation.

Authors:  Eric J Chow; K Scott Baker; Stephanie J Lee; Mary E D Flowers; Kara L Cushing-Haugen; Yoshihiro Inamoto; Nandita Khera; Wendy M Leisenring; Karen L Syrjala; Paul J Martin
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

10.  A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.

Authors:  Nikoletta Lendvai; Patrick Hilden; Sean Devlin; Heather Landau; Hani Hassoun; Alexander M Lesokhin; Ioanna Tsakos; Kaitlyn Redling; Guenther Koehne; David J Chung; Wendy L Schaffer; Sergio A Giralt
Journal:  Blood       Date:  2014-06-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.